Oral vinorelbine: Role in the management of metastatic breast cancer

Drugs

Volumn 67, Issue 5, 2007, Pages 657-667

  Aapro, Matti S ^a   Conte, Pierfranco ^b   González, Emilio Esteban ^c   Trillet Lenoir, Véronique ^d  

^a Inst Multidisciplinaire d'Oncologie   (Switzerland)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^d CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BEVACIZUMAB; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROPYRIMIDINE; LAPATINIB; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB; VINBLASTINE;

ALOPECIA; ANEMIA; ASTHENIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENTIATION; DRUG RESPONSE; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FLUID RETENTION; HUMAN; INFECTION; LEUKOPENIA; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROMUSCULAR DISEASE; NEUROTOXICITY; NEUTROPENIA; PATIENT COMPLIANCE; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; SENSORY DYSFUNCTION; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; HUMANS; NEOPLASM METASTASIS; TREATMENT OUTCOME; VINBLASTINE;

EID: 34047202064     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200767050-00002     Document Type: Review

References (86)

1. Smith I. Goals of treatment for patients with metastatic breast cancer. Semin Oncol 2006; 33 (1 Suppl. 2): S2-5
2. Gralow JR. Optimizing the treatment of metastatic breast cancer. Breast Cancer Res Treat 2005; 89 Suppl. 1: S9-S15
3. Guarneri V, Conte PF. The curability of breast cancer and the treatment of advanced disease. Eur J Nucl Med Mol Imaging 2004; 31 Suppl. 1: S149-61
4. Fallowfield L, Atkins L, Catt S, et al. Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer. Ann Oncol 2006; 17 (2): 205-10
5. Liu G, Franssen E, Fitch MI, et al. Patient preference for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15 (1): 110-5
6. Catania C, Didier F, Leon ME, et al. Perception that oral anticancer treatments are less efficacious: development of a questionnaire to assess the possible prejudices of patients with cancer. Breast Cancer Res Treat 2005; 92: 265-72
7. Ayash LJ, Wheeler C, Fairclough D, et al. Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. J Clin Oncol 1995; 13 (8): 2043-9
8. van der Wall E, Horn T, Bright E, et al. Autologous graft-versus-host disease induction in advanced breast cancer: role of peripheral blood progenitor cells. Br J Cancer 2000; 83 (11): 1405-11
9. Seidman AD. Monotherapy options in the management of metastatic breast cancer. Semin Oncol 2003; 30 (2 Suppl. 3): 6-10
10. Perez EA. Paclitaxel in breast cancer. Oncologist 1998; 3: 373-89
11. Figgitt DP, Wiseman LR. Docetaxel: an update of its use in advanced breast cancer. Drugs 2000; 59: 621-51
12. Eniu A, Palmieri FM, Perez EA. Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer. Oncologist 2005; 10 (9): 665-85
13. Paridaens R, Biganzoli L, Bruning P, et al. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol 2000; 18: 724-33
14. Fumoleau P, Delgado FM, Delozier T, et al. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 1993; 11 (7): 1245-52
15. Garcia-Conde J, Lluch A, Martin M, et al. Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy. Ann Oncol 1994; 5: 854-7
16. Twelves CJ, Dobbs NA, Curnow A, et al. A phase II, multicenter, UK study of vinorelbine in advanced breast cancer. Br J Cancer 1994; 70: 990-3
17. Romero A, Rabinovich MG, Vallejo CT, et al. Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J Clin Oncol 1994; 12 (2): 336-41
18. Bruno S, Lira Puerto V, Mickiewicz E, et al. Phase II trial of weekly IV vinorelbine as single agent in first-line advanced breast cancer chemotherapy: the Latin-American experience. Am J Clin Oncol 1995; 18 (5): 392-6
19. Weber L, Vogel C, Jones S, et al. Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol 1995; 13 (11): 2722-30
20. Terenziani M, Demicheli R, Brambilla C, et al. Vinorelbine: an active, non-cross-resistant drug in advanced breast cancer: results from a phase II study. Breast Cancer Res Treat 1996; 39: 285-91
21. Vogel C, O'Rourke M, Winer E, et al. Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older. Ann Oncol 1999; 10 (4): 397-402
22. Zelek L, Barthier S, Riofrio M, et al. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer 2001; 92 (9): 2267-72
23. Udom DI, Vigushin DM, Linardou H, et al. Two weekly vinorelbine: administration in patients who have received at least two prior chemotherapy regimes for advanced breast cancer. Eur J Cancer 2000, 82
24. Barni S, Ardizzoia A, Bernardo G, et al. Vinorelbine as single agent in pretreated patients with advanced breast cancer. Tumori 1994; 80 (4): 280-2
25. Degardin M, Bonneterre J, Jecquet B, et al. Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer. Ann Onocl 1994; 5 (5): 423-6
26. Gasparini G, Caffo O, Barni S, et al. Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study. J Clin Oncol 1994; 12 (10): 2094-101
27. Fazeny B, Zifko U, Meryn S, et al. Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel: a phase II study. Cancer Chemother Pharmacol 1996; 39 (1-2): 150-6
28. Nistico C, Garufi C, Milella M, et al. Weekly schedule of vinorelbine in pretreated breast cancer patients. Breast Cancer Res Treat 2000; 59 (3): 223-9
29. Crown J, Dieras V, Kaufmann M, et al. Chemotherapy for metastatic breast cancer-report of a European expert panel. Lancet Oncol 2002; 3 (12): 719-27
30. De Pas T, Sbanotto A, Catania C, et al. Oral administration of vinorelbine can overcome intractable endovenous-vinorelbine-associated acute tumor pain. Support Care Cancer 2005; 13 (3): 194-5
31. Mano M. Vinorelbine in the management of breast cancer: new perspectives, revived role in the era of targeted therapy. Cancer Treat Rev 2006; 32 (2): 106-18
32. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. NEJM 2001; 11: 783-92
33. Seidman AD, Fornier MN, Esteva FJ, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001; 19 (10): 2587-95
34. Esteva FJ, Valero V, Booser D, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20 (7): 1800-8
35. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005; 23 (19): 4265-74
36. Pegram MD, Konecny GE, O'Callaghan C, et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004; 96 (10): 739-49
37. Montemurro F, Valabrega G, Aglietta M. Trastuzumab-based combination therapy for breast cancer. Expert Opin Pharmacother 2004; 5 (1): 81-96
38. De Laurentiis M, Cancello G, Zinno L, et al. Targeting HER2 as previa therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology. Ann Oncol 2005; 16 Suppl. 4: iv7-iv13
39. Rugo HS. Bevacizumab in the treatment of breast cancer: rationale and current data. Oncologist 2004; 9 Suppl. 1: 43-9
40. de Gramont A, Cutsem E. Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer. Oncology 2005; 69 Suppl. 3: 46-56
41. Moy B, Goss PE. Lapatinib: current status and future directions in breast cancer. Oncologist 2006; 11 (10): 1047-57
42. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23 (4): 792-9
43. Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumour effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006; 24 (5): 769-77
44. Marty M, Fumoleau P, Adenis A, et al. Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumours. Ann Oncol 2001; 12: 1643-9
45. Variol P, Nguyen L, Tranchard B, et al. A simultaneous oral/intravenous population pharmacokinetics model for vinorelbine. Eur J Clin Pharmacol 2002; 58: 467-76
46. Jassem J, Kosmidis P, Ramiau R, et al. Oral vinorelbine in combination with cisplatin: a novel active regimen in advanced non-small-cell lung cancer. Ann Oncol 2003; 14 (11): 1634-9
47. Freyer G, Delozier T, Lichinister M, et al. Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 2003; 21: 35-40
48. Amadori D, Koralewski P, Tekiela A, et al. Efficacy and safety of navelbine oral (NVBO) in first line metastatic breast cancer (MBC) [abstract]. Eur J Cancer 2001; 37 Suppl. 6: 195
49. Multinational Association of Supportive Care in Cancer. The 2004 Perugia Antiemetic Consensus Guidelines. Support Care Cancer 2005; 13 (2): 77-132
50. Bartsch R, Wenzel C, Pluschnig U, et al. Oral vinorelbine alone or in combination with trastuzumab in advanced breast cancer: results from a pilot trial. Cancer Chemother Pharmacol 2006; 57: 554-8
51. Baweja M, Suman VJ, Fitch TR, et al. Phase II trial of oral vinorelbine for the treatment of metastatic breast cancer in patients ≥65 years of age: an NCCTG study. Ann Oncol 2006; 17: 623-9
52. Carelle N, Piotto E, Bellanger A, et al. Changing patient perceptions of the side effects of cancer chemotherapy. Cancer 2002; 95 (1): 155-63
53. Coates AS, Stockler M, Wilcken N. Controversies in metastatic breast cancer: optimal duration of chemotherapy. ASCO Educational Handbook 2003: 119-21
54. Sikov WM, Akerley W, Kahanic S, et al. Multicenter, 3-arm randomized study of high-dose weekly paclitaxel versus standard-dose weekly paclitaxel for metastatic breast cancer [abstract]. Proceedings of the 38th Annual Meeting of the American Society of Clinical Oncology; 2002 May 18; Orlando (FL): 34
55. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxirubicin-induced congestive heart failure. Ann Intern Med 1979; 91 (5): 710-7
56. Brugnatelli S, Riccardi A, Danova M, et al. Sequential docetaxel and vinorelbine for patients with advanced breast cancer previously treated with anthracyclines: a phase II study. Oncol Rep 2001; 8 (4): 801-5
57. Gralow JR, Ellis GK, Williams MA, et al. Docetaxel + vinorelbine with concurrent G-CSF support: a phase II study in stage IV breast cancer [abstract]. Proceedings of the 36th Annual Meeting of the American Society of Clinical Oncology; 2000 May 20-23; New Orleans (LA)
58. Kornek GV, Ulrich-Pur H, Penz M, et al. Treatment of advanced breast cancer with vinorelbine and docetaxel with or without human granulocyte colony-stimulating factor. J Clin Oncol 2001; 19 (3): 621-7
59. Rodriguez J, Calvo E, Cortes J, et al. Docetaxel plus vinorelbine as salvage chemotherapy in advanced breast cancer: a phase II study. Breast Cancer Res Treat 2002; 76 (1): 47-56
60. Sambiasi D, Misino A, Silvestris N, et al. A phase I study of vinorelbine plus capecitabine in patients with advanced breast cancer [abstract no. 2001]. Ann Oncol 2002; 13 Suppl. 5: 56
61. Welt A, Von Minckwitz C, Oberhoff C, et al. Phase I-II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer. Ann Oncol 2005; 16: 64-9
62. Ahn JH, Kim SB, Kim TW, et al. Capecitabine and vinorelbine in patients metastatic breast cancer previously treated with anthracycline and taxane. J Korean Med Sci 2004; 19: 547-53
63. Ghosn M, Chahine M, Kattan G, et al. Phase II study of sequential administration of vinorelbine-capecitabine followed by weekly docetaxel as first line chemotherapy in metastatic breast cancer [abstract no. 817]. Proc Am Soc Clin Oncol 2004; 23: 80
64. Stuart N, Bishop JL, Johnson SRP, et al. Vinorelbine and capecitabine (VX) for advanced breast cancer: a phase II study showing good activity and potential for further development [abstract no. 183]. Proc Am Soc Clin Oncol 2003; 22: 46
65. Domenech GH, Perez A, Vogel CL. Vinorelbine/capecitabine (VINOCAP) combination remission induction therapy for metastatic breast cancer (MBC) [abstract no. 1939]. Proc Am Soc Clin Oncol 2001; 20: 48
66. Nolé F, Catania C, Sanna G, et al. Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer. Ann Oncol 2006; 17: 322-9
67. Nolé F, Catania C, Sanna G, et al. Phase II study with dose finding of oral vinorelbine in combination with capecitabine as first line chemotherapy of metastatic breast cancer (MBC): preliminary results of the phase II part of the study [abstract no. 408]. Eur J Can 2006; Suppl. 4
68. Finek K, Holubec L, Elgrova L, et al. The effect of oral vinorelbine and capecitabine in patients with metastatic breast cancer. J Clin Oncol (Meeting Abstracts) 2006; 24 (18S): 10605
69. Delcambre C, Veyret C, Levy C, et al. A phase I/II study of capecitabine combined with oral vinorelbine as first- or second-line therapy in locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2005; 94: Suppl. 1: P1081
70. Chan A, Tubiana N, Ganju V, et al. Optimal tolerance of an all-oral combination chemotherapy of oral vinorelbine (NVBo), capecitabine (C) with/without trastuzumab (T) in metastatic breast cancer (MBC) patients (pts): safety results of two international multicenter studies. J Clin Oncol (Meeting Abstracts) 2006; 24 (18S): 10607
71. Emens LA. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer. Am J Ther 2005; 12 (3): 243-53
72. Gasparini G, Longo R, Torino F, et al. Therapy of breast cancer with molecular targeting agents. Ann Oncol 2005; 16 Suppl. 4: iv28-36
73. Rueckert S, Ruehl I, Kahlert S, et al. A monoclonal antibody as an effective therapeutic agent in breast cancer: trastuzumab. Expert Opin Biol Ther 2005; 5 (6): 853-66
74. Pegram MD, Hsu S, Lewis G, et al. Inhibitory effects of combination of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999; 18 (13): 2241-51
75. Jahanzeb M. Trastuzumab-based combinations in metastatic breast cancer: how to make a choice. Clin Breast Cancer 2003; 1: 28-38
76. Perez EA, Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol 2004; 22 (2): 322-9
77. Suter TM, Cook-Bruns N, Barton C. Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. Breast 2004; 13 (3): 173-83
78. Untch M, Eidtmann H, du Bois A, et al. Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial. Eur J Cancer 2004; 40 (7): 988-97
79. Burstein HJ, Harris LN, Marcom PK, et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003; 21 (15): 2889-95
80. Burstein HJ, Kuter I, Campos SM, et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001; 19 (10): 2722-30
81. Jahanzeb M, Mortimer JE, Yunus F, et al. Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer. Oncologist 2002; 7 (5): 410-7
82. Bernardo G, Palombo R, Bernardo A. Weekly trastuzumab (Herceptin) and vinorelbine (Navelbine) in chemonaive patients with HER2-overexpressing metastatic breast cancer: a phase II trial [abstract]. Ann Oncol 2002; 13: 51
83. Suzuki Y, Tokuda Y, Saito Y, et al. Combination of trastuzumab and vinorelbine in metastatic breast cancer. Jpn J Clin Oncol 2003; 33: 514-7
84. Fountzilas G, Tsavdaridis D, Kalogera-Fountzila A, et al. Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer: a Hellenic Cooperative Oncology Group phase II study. Ann Oncol 2001; 12 (11): 1545-51
85. Janku F, Pribylova O, Zimovjanova M, et al. 4-years results of weekly trastuzumab and paclitaxel in the treatment of women with HER2/neu overexpressing advanced breast cancer: single institution prospective study. Bull Cancer 2004; 91 (10): E279-83
86. Chan A, Tubiana N, Ganju V, et al. Optimal tolerance of an all-oral combination chemotherapy (CT) of oral viorelbine (NVBo), capecitabine (C) with/without trastuzumab (T) in metastatic breast cancer (MBC) patients (pts): safety results of two international multicenter studies [abstract no. 10607]. Proc Annu Meet Am Soc Clin Oncol 2006; 24 (18s): 576s